Non-peptide arginine-vasopressin antagonists: the vaptans

The Lancet

Volumn 371, Issue 9624, 2008, Pages 1624-1632

  Decaux, Guy ^a   Soupart, Alain ^b   Vassart, Gilbert ^c  

^a ERASME HOSPITAL   (Belgium)

^b Tubize Jolimont Hospital   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; ARGIPRESSIN DERIVATIVE; ARGIPRESSIN RECEPTOR; CONIVAPTAN; FUROSEMIDE; LIXIVAPTAN; MOZAVAPTAN; PEPTIDE HORMONE ANTAGONIST; PROTEIN V1A; PROTEIN V1B; PROTEIN V2; RELCOVAPTAN; SATAVAPTAN; TOLVAPTAN; VAPTAN DERIVATIVE;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIURESIS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSMENORRHEA; ELECTROLYTE EXCRETION; FLUID BALANCE; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPONATREMIA; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; LIVER CIRRHOSIS; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; TOCOLYSIS;

EID: 43049146180     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60695-9     Document Type: Review

References (79)